None listed
Conditions
Interventions
None listed
Sponsors
Samsung Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with histopathologically confirmed DLBCL 2.Patients diagnosed with DLBCL who relapsed or were refractory to first-line treatment with rituximab-based immunotherapy 3.Patients available for genomic analysis of tissues both at diagnosis (paraffin-embedded and stored) and at relapse (paraffin-embedded) 4.Patients aged =18 years 5.Patients who provide written informed consent for participation in the prospective cohort study 6.Patients who provide written informed consent to peripheral blood collection and genetic testing of human tissues
Exclusion criteria
Exclusion criteria: 1.Patients who have no lymphoid malignancy, e.g. myeloid leukemia 2.Patients with any of the following lymphoid malignancies: 1)Plasma cell dyscrasia, amyloidosis 2)Hodgkin lymphoma 3)Subtypes of B cell non-Hodgkin lymphoma, other than DLBCL 4)T or NK cell non-Hodgkin lymphoma 5)Other diseases in the WHO classification of lymphoid malignancies 3.Patients who have experienced a relapse before 4.Patients with insufficient or no tissue sample at diagnosis for genomic analysis 5.Patients who do not understand or provide written informed consent 6.Patients who do not provide written informed consent to blood collection and genetic testing
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate response and survival following a salvage therapy depending on the genomic sequencing results, and to investigate the prognostic or predictive value of genomic mutation. | — |
Secondary
| Measure | Time frame |
|---|---|
| To investigate the response to salvage chemotherapy and survival outcome.;To determine the association between gene mutation, treatment response and prognosis. | — |
Countries
Korea, Republic of
Contacts
Public ContactWon Seog Kim
Samsung Medical Center
Outcome results
None listed